User profiles for Andrew Woolston
Andrew WoolstonInstitute of Cancer Research, London Verified email at icr.ac.uk Cited by 1128 |
[PDF][PDF] Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer
Despite biomarker stratification, the anti-EGFR antibody cetuximab is only effective against
a subgroup of colorectal cancers (CRCs). This genomic and transcriptomic analysis of the …
a subgroup of colorectal cancers (CRCs). This genomic and transcriptomic analysis of the …
[HTML][HTML] Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or …
…, J Michaux, HS Pak, BJ Stevenson, A Woolston… - … for immunotherapy of …, 2019 - Springer
Background Patient derived organoids (PDOs) can be established from colorectal cancers (CRCs)
as in vitro models to interrogate cancer biology and its clinical relevance. We applied …
as in vitro models to interrogate cancer biology and its clinical relevance. We applied …
Do bone grafts or barrier membranes provide additional treatment effects for infrabony lesions treated with enamel matrix derivatives? A network meta‐analysis of …
YK Tu, A Woolston… - Journal of clinical …, 2010 - Wiley Online Library
Background/Aim: Network meta‐analyses of randomized‐controlled trials were undertaken
to investigate whether enamel matrix derivatives (EMD) in conjunction with other …
to investigate whether enamel matrix derivatives (EMD) in conjunction with other …
[HTML][HTML] CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient …
Background The T cell bispecific antibody cibisatamab (CEA-TCB) binds Carcino-Embryonic
Antigen (CEA) on cancer cells and CD3 on T cells, which triggers T cell killing of cancer cell …
Antigen (CEA) on cancer cells and CD3 on T cells, which triggers T cell killing of cancer cell …
[HTML][HTML] Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer
Mismatch repair deficient (dMMR) gastro-oesophageal adenocarcinomas (GOAs) show better
outcomes than their MMR-proficient counterparts and high immunotherapy sensitivity. The …
outcomes than their MMR-proficient counterparts and high immunotherapy sensitivity. The …
[HTML][HTML] Pathobionts in the tumour microbiota predict survival following resection for colorectal cancer
Background and aims The gut microbiota is implicated in the pathogenesis of colorectal
cancer (CRC). We aimed to map the CRC mucosal microbiota and metabolome and define the …
cancer (CRC). We aimed to map the CRC mucosal microbiota and metabolome and define the …
Ultra-sensitive mutation detection and genome-wide DNA copy number reconstruction by error-corrected circulating tumor DNA sequencing
…, SY Moorcraft, M Davidson, A Woolston… - Clinical …, 2018 - academic.oup.com
BACKGROUND Circulating free DNA sequencing (cfDNA-Seq) can portray cancer genome
landscapes, but highly sensitive and specific technologies are necessary to accurately …
landscapes, but highly sensitive and specific technologies are necessary to accurately …
Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer
A Woolston, LJ Barber, B Griffiths, O Pich… - Nature ecology & …, 2021 - nature.com
Anti-EGFR antibodies such as cetuximab are active against KRAS/NRAS wild-type
colorectal cancers (CRCs), but acquired resistance invariably evolves. It is unknown which …
colorectal cancers (CRCs), but acquired resistance invariably evolves. It is unknown which …
Genetic and immune landscape evolution in MMR‐deficient colorectal cancer
BR Challoner, A Woolston, D Lau… - The Journal of …, 2024 - Wiley Online Library
Mismatch repair‐deficient (MMRd) colorectal cancers (CRCs) have high mutation burdens,
which make these tumours immunogenic and many respond to immune checkpoint inhibitors…
which make these tumours immunogenic and many respond to immune checkpoint inhibitors…
Computational image analysis of T-cell infiltrates in resectable gastric cancer: association with survival and molecular subtypes
BR Challoner, K von Loga, A Woolston… - JNCI: Journal of the …, 2021 - academic.oup.com
Background Gastric and gastro-esophageal junction cancers (GCs) frequently recur after
resection, but markers to predict recurrence risk are missing. T-cell infiltrates have been …
resection, but markers to predict recurrence risk are missing. T-cell infiltrates have been …